Cg Oncology Inc. (CGON)

$35.91

+0.38

(+1.07%)

Market is closed - opens 7 PM, 04 Nov 2024

Performance

  • $35.22
    $36.60
    $35.91
    downward going graph

    1.91%

    Downside

    Day's Volatility :3.76%

    Upside

    1.89%

    downward going graph
  • $25.77
    $50.23
    $35.91
    downward going graph

    28.24%

    Downside

    52 Weeks Volatility :48.7%

    Upside

    28.51%

    downward going graph

Returns

PeriodCg Oncology Inc.Index (Russel 2000)
3 Months
15.8%
0.0%
6 Months
-0.99%
0.0%
1 Year
-3.39%
0.0%
3 Years
-3.39%
-26.4%

Highlights

Market Capitalization
2.4B
Wall Street Target Price
68.2
Profit Margin
0.0%
Operating Margin TTM
-4247.45%
Return On Assets TTM
0.0%
Return On Equity TTM
0.0%
Revenue TTM
539.0K
Revenue Per Share TTM
0.04
Quarterly Revenue Growth YOY
172.70000000000002%
Gross Profit TTM
0.0
EBITDA
-68.2M
Diluted Eps TTM
0.0
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-1.59
EPS Estimate Next Year
-1.89
EPS Estimate Current Quarter
0.0
EPS Estimate Next Quarter
0.0

Analyst Recommendation

Buy
    81%Buy
    18%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Cg Oncology Inc.(by analysts ranked 0 to 5 stars)

Analyst Forecast

What analysts predicted

Upside of 89.92%

Current $35.91
Target $68.20

Technicals Summary

Sell

Neutral

Buy

Cg Oncology Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Cg Oncology Inc.
Cg Oncology Inc.
-0.14%
-0.99%
-3.39%
-3.39%
-3.39%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-16.85%
-11.85%
3.27%
29.37%
171.22%
Biontech Se
Biontech Se
-6.94%
20.23%
16.39%
-62.26%
487.66%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
1.63%
79.81%
63.67%
58.45%
198.57%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.87%
17.46%
25.23%
149.18%
136.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Cg Oncology Inc.
Cg Oncology Inc.
NA
NA
NA
-1.59
0.0
0.0
NA
NA
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
20.75
20.75
1.18
44.77
0.17
0.08
NA
242.47
Biontech Se
Biontech Se
160.8
NA
0.04
-2.76
-0.03
-0.02
NA
80.22
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
NA
NA
-0.49
-2.39
-15.01
0.02
NA
-0.02
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
32.84
NA
1.21
0.16
-0.03
0.13
NA
57.26
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Cg Oncology Inc.
Cg Oncology Inc.
Buy
$2.4B
-3.39%
NA
0.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$101.7B
171.22%
20.75
32.04%
Biontech Se
Biontech Se
Buy
$27.1B
487.66%
160.8
-18.75%
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc.
Buy
$36.5B
198.57%
NA
-3.11%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$122.9B
136.25%
32.84
-4.74%

Corporate Announcements

  • Cg Oncology Inc. Earnings

    Cg Oncology Inc.’s price-to-earnings ratio stands at None

    Read More

Company Information

Organization
Cg Oncology Inc.
Employees
61
CEO
Mr. Arthur Kuan
Industry
Miscellaneous

FAQs